Headquarters Australia | ||
 | ||
Stock price AVIR (NASDAQ) US$ 0.60 +0.01 (+1.33%)1 Mar, 4:00 PM GMT-5 - Disclaimer Profiles | ||
Biota holdings plans merger for nasdaq listing
Biota was an Australian antiviral drug development company was listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.
In November 2012, Biota Holdings Limited merged with American company Nabi Biopharmaceuticals to form Biota Pharmaceuticals.
ATLANTA, 12 April 2016: Biota Pharmaceuticals, Inc. (NASDAQ:AVIR was BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., ("Aviragen Therapeutics"), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections that have limited therapeutic options.